Loading clinical trials...
Loading clinical trials...
The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis
Conditions
Interventions
Fingolimod
Locations
61
United States
Novartis Investigative Site
Fort Lauderdale, Florida, United States
Novartis Investigative Site
Cambridge, Massachusetts, United States
Novartis Investigative Site
Grand Forks, North Dakota, United States
Novartis Investigative Site
Bahía Blanca, Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Box Hill, Victoria, Australia
Start Date
October 15, 2011
Primary Completion Date
May 29, 2024
Completion Date
May 29, 2024
Last Updated
January 22, 2025
NCT07325292
NCT05748015
NCT04876339
NCT05344469
NCT07225504
NCT06276634
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions